Rep. Maria Elvira Salazar (R-FL) Sells Moderna (MRNA) Stock

Congresswoman Maria Elvira Salazar sold shares of Moderna, Inc. (MRNA) on September 24, 2026. The transaction was valued between $1,001 and $15,000 and was reported on October 7, 2026.

Inside Maria Elvira Salazar's Trade

Salazar's sale of Moderna shares comes as the stock has been performing well. The recent trading price was around $212.26 as of October 16, 2026, which is significantly above its 50-day moving average of about $148.05 and its 200-day moving average of about $75.43.

Other Institutional Activity in Moderna

Several other institutional investors have also been active in Moderna. FMR, LLC increased its stake by 6,188,477 shares, bringing its total to about 51.9 million shares valued at approximately $11.3 billion. Blackrock Inc. added 963,178 shares, totaling about 30.6 million shares worth about $6.7 billion. Vanguard Capital Management LLC also grew its holdings by 336,227 shares, ending with about 23.2 million shares valued at around $5.1 billion. Capital World Investors increased its share count by 3,578,829 shares, totaling about 22.3 million shares worth about $4.9 billion. Baillie Gifford & Co, however, trimmed its position by 1,778,708 shares, bringing its total to about 18.2 million shares valued at approximately $3.97 billion.

Moderna, Inc. Stock Down 3.7%

As of October 16, 2026, Moderna's stock traded at $212.26, which is above both its 50-day and 200-day moving averages. However, it is about 12.4% below its 52-week high of $242.29. With a market cap of approximately $94.4 billion, Moderna is a key player in the biotechnology sector, known for its mRNA medicines.

Recent Earnings

In its latest earnings report, Moderna posted a trailing twelve-month revenue of about $2.23 billion, reflecting a year-over-year growth of 2.1%. The company reported an EPS of -$7.98, indicating it has not been profitable recently. The next earnings report is expected on November 6, 2026.

Insider Buying and Selling at Moderna, Inc.

Several insiders have sold shares recently. CEO Stephane J. Bancel sold 499,246 shares valued at about $28.7 million on August 5, 2026. Officer Shannon Thyme Klinger sold 3,471 shares at an average price of $139.95, totaling around $485,766 on September 1, 2026. CFO James M. Mock sold 34,836 shares at $134.49, amounting to about $4.7 million on September 10, 2026. President Stephen Hoge sold 80,575 shares valued at about $11.7 million on September 15, 2026.

Analysts Set New Price Targets

Analysts have been adjusting their views on Moderna. On August 21, 2026, JP Morgan maintained an "Underweight" rating with a price target of $77. On August 24, Barclays also maintained an "Equal-Weight" rating with a target of $125. Wolfe Research upgraded its rating to "Peer Perform" on August 25, while Argus Research upgraded to "Buy" with a target of $180 on August 28. Rothschild & Co downgraded its rating to "Sell" with a target of $81 on September 3.

About Moderna, Inc.

Moderna, Inc. is a biotechnology company based in Cambridge, MA. It specializes in developing messenger RNA (mRNA) medicines. The company's innovative approach has positioned it as a significant player in the healthcare sector, especially with its focus on vaccines and therapies.

Bottom Line

Maria Elvira Salazar's recent sale of Moderna shares adds to her prior stock transactions, including sales of United Rentals, RH, and Peloton on the same day. Investors will be watching Moderna’s next earnings report due on November 6, 2026, for further insights into its performance.